The #BCLC2026 conversation doesn’t start on November 16 — and it doesn’t end on November 17.
✨ Introducing the BCLC 2026 Scientific Exchange, a dedicated space for registered participants to connect, discuss and engage with the science before and after the meeting.
🔬 Explore scientific resources
💬 Join the discussion
🤝 Exchange perspectives
🎥 Revisit key sessions after the congress
The meeting lasts two days. The scientific conversation goes far beyond.
Welcome to the BCLC Update 2026 Scientific Exchange.
The CUSE concept serves the need to recommend the optimal therapy for an individual patient.
An honor to have it supported in China.
@hospitalclinic@idibaps@EASLnews@ILCAnews
🔥 Great time in China for #CACA!
Inspiring discussions at the CACA International Liver Cancer Symposium,
especially gaining valuable insights from Prof. Maria Reig @ma5RN on the updated #BCLC guidelines and the #CUSE framework.
#LiverX#HCC
20 years of activity mean maturity and great future. Great to see @ma5RN@MarcoSanduzzi and @bruixj from the BCLC in the picture. Transgeneration involvement!!
The wait is over #ILCA26!
Opened by President Prof. Stephen Lam Chan with a special tribute to past leaders, Day 1 featured key updates on Bench to Bedside care, the Asian experience and joint KLCA surgical session.
Day 2 continues today!
🔗 ilcalive.org/annual-conferen…
Successful advocacy task by @ILCAnews organised by @allaire_manon A call to action on liver cancer raised through a document to be debated at the European level. It will be open for comments at the ILCA website. A needed development.
The Pan-Asian adapted ESMO CPGs for HCC DOI: 10.1016/j.esmoop.2025.105826 endorse the BCLC for prognosis & treatment recommendations. The modulations mimic the BCLC update with CUSE concept pubmed.ncbi.nlm.nih.gov/4115… The start of a global consensus.
@hospitalclinic@idibaps
🆕An international study led by #CLÍNIC-#IDIBAPS shows that external beam radiotherapy can offer survival outcomes comparable to those of current local treatments for hepatocellular carcinoma, the most common type of liver cancer
👉f.mtr.cool/wczzrlljqj
📊 La radioteràpia externa pot oferir una supervivència similar als tractaments locals establerts en el càncer de fetge, especialment en estadis inicials.
🔹Aquesta és una de les conclusions d’un estudi internacional amb dades de prop de 5️⃣0️⃣0️⃣0️⃣ pacients, el més ampli fet fins a la data en aquest àmbit.
🔹L'ha coordinat la Unitat d’Oncologia Hepàtica @BCLC_group del #CLÍNIC-@idibaps, en el marc del #ClínicBarcelonaComprehensiveCancerCentre.
👉clinicbarcelona.org/ca/notic…
Clinical practice forces us to face the complexity of decision making to reach an optimal recommendation. This is the reason to develop the bclccuse.ai/ to inform decisions. All presented by @ma5RN also at the Shanghai APPLE meeting @hospitalclinic@idibaps
Selecting appropriate strategy #HCC@ma5RN giving fabulous BCLC overview- navigating early/intermediate
➡️combos no OS benefit to date
➡️Using CUSE & available evidence to help select tools at MDT
➡️noting the ‘real world’ patient & the patient preference
#ESMOGI26@OncoAlert
🎙️ The new Y-ILCA Podcast is officially live!
Ep. 1: Trailblazers in Liver Cancer
Join host Dr. Joana Espírito Santo in conversation with a true legend: Prof. Jordi Bruix, ILCA Co-Founder & BCLC creator.
🔗Listen to the premiere episode: open.spotify.com/episode/6Zv…
Today Carla Fuster MD obtained her PhD after a brilliant exposure of pathology profiling of liver cancer. Great work mentored by @ma5RN & Prof Alba Diaz. A promising career ahead. Colleagues and family are proud and happy!! @hospitalclinic@idibaps@APClinicBCN
Major international IPD effort by @ma5RN@AndrewMMoon and @tedradonc crafting a great team to assess the survival of almost 5000 HCC patients treated with EBRT and stratified by BCLC stage. Best information available to consider EBRT in clinical practice
pubmed.ncbi.nlm.nih.gov/4213…